GLP-1 Agonist + Levonorgestrel IUD for Endometrial Hyperplasia

This trial tests a new approach to treat endometrial hyperplasia, a condition where the uterine lining becomes excessively thick and may lead to cancer. The study combines a GLP-1 receptor agonist, a medication that aids in weight loss and lowers blood sugar, with a levonorgestrel IUD, a device that releases hormones to thin the uterine lining. This trial suits individuals recently diagnosed with early-stage endometrial cancer who seek fertility preservation or cannot undergo surgery. Participants should have a body mass index (BMI) of 30 or higher, with no cancer spread beyond the uterus. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss your specific situation with the study team or your doctor.

Research has shown that GLP-1 receptor agonists, medications that mimic a natural hormone, are generally well-tolerated. In a large study involving over 1.6 million patients, those using these medications had a 26% lower risk of developing endometrial cancer compared to non-users. This suggests the treatment might be safe for people.

Another study found that combining GLP-1 receptor agonists with another treatment significantly reduced the risk of developing endometrial cancer. These studies reported no major side effects, supporting the safety of GLP-1 receptor agonists for most people.

Unlike the standard treatments for endometrial hyperplasia, which often involve hormonal therapy with progestins or surgical interventions, the GLP-1 agonist offers a unique approach. This treatment leverages a glucagon-like peptide 1 receptor agonist, typically used for diabetes and weight management, to target endometrial tissue in a novel way. Researchers are excited because GLP-1 agonists may help reverse hyperplasia by influencing metabolic pathways that are not addressed by current hormonal treatments. This could potentially offer a non-surgical, hormone-free option with a different mechanism of action, providing new hope for patients.

Research has shown that combining GLP-1 receptor agonists with progestins can reduce the need for a hysterectomy in patients with endometrial hyperplasia. One study found that this therapy lowered the likelihood of requiring a hysterectomy by nearly half after two years and by about 40% after five years. GLP-1 receptor agonists, which participants in this trial may receive, also reduce inflammation and scarring in the uterine lining. Additionally, these medications might lower the risk of developing endometrial cancer, suggesting they could be a promising option for managing endometrial hyperplasia without surgery.³⁴⁶⁷⁸